WebFeb 6, 2024 · VANCOUVER, Feb. 6, 2024 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercializati... WebAug 23, 2024 · Sierra Oncology Inc. acquired myelofibrosis drug momelotinib from Gilead Sciences Inc. Myelofibrosis is a type of cancer in the bone marrow that disrupts the body's normal production of blood cells, resulting in extensive scarring of the bone marrow. The disorder is often characterized by severe anemia, weakness, fatigue and an enlarged …
A Study of Momelotinib Versus Danazol in Symptomatic and …
WebFeb 11, 2024 · Gilead Sciences, Inc. (NASDAQ: GILD) disclosed in a filing with the SEC a 9.99% stake in Sierra Oncology Inc (NASDAQ: SRRA). Gilead shares slipped 0.14% to $68.89 in after-hours trading, while ... WebJan 25, 2024 · Sierra Oncology announced Tuesday that a Phase III study of the experimental drug momelotinib in certain patients with myelofibrosis met all of its primary and key secondary endpoints, ... Gilead cast-off. Sierra noted that momelotinib is the first JAK inhibitor to demonstrate positive data for myelofibrosis symptoms, ... list of missions strangers of paradise
SIERRA ONCOLOGY, INC. : Stock Market News and Information
WebAug 22, 2024 · Current members of Sierra's management team have prior experience … WebApr 16, 2024 · GlaxoSmithKline has agreed to acquire Sierra Oncology for $1.9 billion. Based in California, ... Sierra acquired the compound from Gilead Sciences in 2024 for $3 million up front. WebApr 14, 2024 · Reporting to the Senior Director, Global Value and Access Oncology HEOR (Lung, Hematology & GI), the Director role will: • Lead the development and implementation of global HEOR strategies and programs to support the launch of a Gilead Oncology product in lung cancer. • Provide HEOR expertise and leadership to inform, support and strengthen ... imdb technical specifications